首页> 美国卫生研究院文献>Evidence-based Complementary and Alternative Medicine : eCAM >A Single-Center Randomized Double-Blind Placebo-Controlled Study Evaluating the Effects of Poly-Gamma-Glutamate on Human NK Cell Activity after an 8-Week Oral Administration in Healthy Volunteers
【2h】

A Single-Center Randomized Double-Blind Placebo-Controlled Study Evaluating the Effects of Poly-Gamma-Glutamate on Human NK Cell Activity after an 8-Week Oral Administration in Healthy Volunteers

机译:一项单中心随机双盲安慰剂对照的研究评估了在健康志愿者进行8周口服给药后聚-γ-谷氨酸对人NK细胞活性的影响。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A randomized double-blind placebo-controlled immunity study involving 99 healthy volunteers was performed to investigate the effect of poly-γ-glutamate (γ-PGA) on human natural killer (NK) cell activity in peripheral blood. The volunteers were randomly assigned to one of three groups and orally treated with solutions (25 mL) containing 0 mg (placebo), 250 mg (low dosage), or 500 mg (high dosage) of γ-PGA. Each volunteer took one dose every 12 hours for 8 weeks. Blood samples were drawn before the initial treatment and at the 4th and the 8th weeks of treatment. NK cell activity was assessed by measuring its degranulation, cytokine production, and cytotoxicity against the K562 cell line. Our results revealed that the cytotoxic activities of NK cells from the high-dosage γ-PGA group were significantly higher (P < 0.05 for all comparisons) compared to the low dosage and placebo groups at weeks 4 and 8 after the initial treatment. This increase in the NK cell activity among peripheral blood mononuclear cells (PBMCs) of healthy individuals was also confirmed in vitro (as assessed by the degranulation and cytokine production). These results suggest that the oral administration of γ-PGA induces a cell-mediated immunity by increasing the NK cell activity in humans.
机译:进行了一项涉及99名健康志愿者的随机双盲安慰剂对照免疫研究,以研究聚γ-谷氨酸(γ-PGA)对外周血中人类自然杀伤(NK)细胞活性的影响。将志愿者随机分配到三组中的一组,并用含0μmg(安慰剂),250μmg(低剂量)或500μmg(高剂量)γ-PGA的溶液(25μmL)口服治疗。每位志愿者每12小时服用一剂,持续8周。在初次治疗之前以及治疗的第4周和第8周抽取血样。 NK细胞活性通过测量其脱颗粒,细胞因子产生和对K562细胞系的细胞毒性来评估。我们的研究结果表明,高剂量γ-PGA组的NK细胞在初始治疗后第4周和第8周的细胞毒性明显高于低剂量和安慰剂组(所有比较,P <0.05)。健康个体的外周血单个核细胞(PBMC)中NK细胞活性的这种增加也已在体外得到证实(通过脱粒和细胞因子产生评估)。这些结果表明,口服γ-PGA可通过增加人的NK细胞活性来诱导细胞介导的免疫。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号